Idioma:

Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia

Ramires, Jose A.F. ; Mansur, Antonio P. ; Solimene, Maria C. ; Maranhão, Raul ; Chamone, Dalton ; da Luz, Protásio ; Pileggi, Fulvio

International journal of cardiology, 1995-02, Vol.48 (2), p.115-120 [Periódico revisado por pares]

Netherlands: Elsevier Ireland Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia
Autor: Ramires, Jose A.F. ; Mansur, Antonio P. ; Solimene, Maria C. ; Maranhão, Raul ; Chamone, Dalton ; da Luz, Protásio ; Pileggi, Fulvio
Assuntos: Adult ; Aged ; Cholesterol - blood ; Female ; Gemfibrozil ; Gemfibrozil - pharmacology ; Gemfibrozil - therapeutic use ; Humans ; Hypercholesterolemia ; Hypercholesterolemia - blood ; Hypercholesterolemia - drug therapy ; Lipoprotein(a) ; Lipoprotein(a) - blood ; Lipoprotein(a) - drug effects ; Lipoproteins, HDL - blood ; Lipoproteins, HDL - drug effects ; Lipoproteins, LDL - blood ; Lipoproteins, LDL - drug effects ; Lipoproteins, VLDL - blood ; Lipoproteins, VLDL - drug effects ; Lovastatin ; Lovastatin - pharmacology ; Lovastatin - therapeutic use ; Male ; Middle Aged ; Treatment Outcome ; Triglycerides - blood
É parte de: International journal of cardiology, 1995-02, Vol.48 (2), p.115-120
Notas: ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-News-3
content type line 23
Descrição: The aim of this study was to determine the effect of gemfibrozil, compared with lovastatin, in patients with high levels of lipoprotein(a) and on plasma lipid profile. Twenty-seven nondiabetic patients with high levels of plasma lipids and lipoprotein(a), 19 male and eight female, aged 37–68 (mean ± S.D. 54.2 ± 7.5) years, were randomly assigned to 12 weeks of treatment with gemfibrozil 600 mg twice daily (14 pts.) or lovastatin 40–80 mg once daily (13 pts.). Patients had fasting plasma total cholesterol levels ≥ 6.2 mmol/l, low-density lipoprotein > 4.14 mmol/l and lipoprotein(a) > 0.62 mmol/l. All patients but one had triglycerides > 2.82 mmol/l. There were no statistical differences between both groups in terms of age, sex, clinical diagnosis and previous medication. After 3 months of treatment, gemfibrozil reduced triglycerides (47.9% vs. 24.5%; P < 0.001), very low density lipoprotein (43.9% vs. 24.6%; P < 0.05), lipoprotein(a) (25.3% vs. 4.9%; P < 0.05) and increased high-density lipoprotein (34.4% vs. 11%; P < 0.01) more than lovastatin. Gemfibrozil and lovastatin reduced comparably total cholesterol (21.4% vs. 29.0%; P = NS) and low-density lipoprotein (26.5% vs. 37.3%; P = NS). The plasma levels of high-density lipoprotein and lipoprotein(a) were unchanged significantly by lovastatin. In conclusion, besides well-known efficacy in hyperlipidemia treatment, gemfibrozil also increased high-density lipoprotein and reduced lipoprotein(a), which may have important epidemiologic implications.
Editor: Netherlands: Elsevier Ireland Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Anterior Resultado 10 Avançar Ir para próxima página

Realização: Logos de Redes Sociais:

Effect of gemfibrozil versus lovastatin on increased serum lipoprotein(a) levels of patients with hypercholesterolemia

Ramires, Jose A.F. ; Mansur, Antonio P. ; Solimene, Maria C. ; Maranhão, Raul ; Chamone, Dalton ; da Luz, Protásio ; Pileggi, Fulvio

Netherlands: Elsevier Ireland Ltd

Buscando em bases de dados remotas. Favor aguardar.